CNS - Taysha Gene's TSHA-105 nabs Orphan Drug tag in Europe

Taysha Gene Therapies (NASDAQ:TSHA) has been granted orphan drug designation from the European Commission for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy, a form of infantile epilepsy. Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, protocol assistance, reduced regulatory, if approved. TSHA-105 is first program in Taysha’s pipeline to receive designation from European Commission

For further details see:

Taysha Gene's TSHA-105 nabs Orphan Drug tag in Europe